DelveInsight’s “Wet Age-Related Macular Degeneration (Wet-AMD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Wet Age-Related Macular Degeneration Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Wet Age-Related Macular Degeneration market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Wet Age-Related Macular Degeneration: An Overview
According to American Macular Degeneration Foundation, Wet Age-Related Macular Degeneration (Wet-AMD) is a type of macular degeneration in which abnormal blood vessels (known as choroidal neovascularization or CNV) develop under the retina and macula. These abnormal blood vessels often grow and leak or bleed, causing scarring of the macula. This damage to the macula results in rapid central vision loss. Once this vision is destroyed, it cannot be restored. Wet AMD results in the exudation or leakage of fluid and blood from new blood vessels and also called neovascular AMD or exudative AMD.
Most AMD starts as the dry type, and in 10-20% of individuals, it progresses to the wet type. Age-related macular degeneration is always bilateral (i.e., it occurs in both eyes) but does not necessarily progress at the same pace in both eyes.
Wet Age-Related Macular Degeneration Market Key Facts
-
According to available literature, females are affected more as compared to males in the case of Wet AMD.
-
As per a study titled “Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future”, (2017), the prevalence of early AMD increased from 3.5% in those aged 55-59 years to 17.6% in those aged ≥85 years; for late AMD these figures were 0.1% and 9.8% respectively.
-
Nearly 11 million Americans have some form of macular degeneration, while 1.1 million or 10% of those Americans have wet AMD.
-
The National Eye Institute (NEI) states that women generally are more susceptible to developing age-related eye diseases, such as AMD. In 2010, 65 percent of total AMD cases were in women as compared to 35 percent in men.
-
The wet/neovascular type affects approximately 10-15% of individuals with age-related macular degeneration but accounts for approximately 90% of all cases of severe vision loss from the disease.
Wet Age-Related Macular Degeneration Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Wet Age-Related Macular Degeneration market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Wet Age-Related Macular Degeneration market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Wet Age-Related Macular Degeneration Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Wet Age-Related Macular Degeneration Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of potential drugs recently launched in the Wet Age-Related Macular Degeneration market or expected to be launched during the study period. The analysis covers Wet Age-Related Macular Degeneration market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Wet Age-Related Macular Degeneration Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Some of the key companies in the Wet Age-Related Macular Degeneration (Wet-AMD) market include:
-
Allergan
-
Bioeq GmbH
-
Alkahest
-
Graybug Vision
-
Eye point pharma
-
Regeneron Pharmaceuticals
And others.
Wet Age-Related Macular Degeneration (Wet AMD) Therapies covered in the report include:
-
Abicipar-pegol
-
FYB201
-
AKST4290
-
GB-102
-
Vorolanib
-
Eylea
And many others.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Wet Age-Related Macular Degeneration Competitive Intelligence Analysis
4. Wet Age-Related Macular Degeneration Market Overview at a Glance
5. Wet Age-Related Macular Degeneration Disease Background and Overview
6. Wet Age-Related Macular Degeneration Patient Journey
7. Wet Age-Related Macular Degeneration Epidemiology and Patient Population
8. Wet Age-Related Macular Degeneration Treatment Algorithm, Current Treatment, and Medical Practices
9. Wet Age-Related Macular Degeneration Unmet Needs
10. Key Endpoints of Wet Age-Related Macular Degeneration Treatment
11. Wet Age-Related Macular Degeneration Marketed Products
12. Wet Age-Related Macular Degeneration Emerging Therapies
13. Wet Age-Related Macular Degeneration Seven Major Market Analysis
14. Attribute Analysis
15. Wet Age-Related Macular Degeneration Market Outlook (7 major markets)
16. Wet Age-Related Macular Degeneration Access and Reimbursement Overview
17. KOL Views on the Wet Age-Related Macular Degeneration Market.
18. Wet Age-Related Macular Degeneration Market Drivers
19. Wet Age-Related Macular Degeneration Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Negative Pressure Wound Therapy Systems Market
“Negative Pressure Wound Therapy Systems Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for the Negative Pressure Wound Therapy Systems. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Negative Pressure Wound Therapy Systems market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/